1574. Multivariate Regression Analysis to Determine Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Trial

BACKGROUND: In the RESTORE-IMI 2 trial, imipenem/cilastatin/relebactam (IMI/REL) was non-inferior to PIP/TAZ for treating hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in the primary endpoint of Day 28 all-cause mortality (D28 ACM) and the key secondary endpoint of clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Tipping, Robert, Du, Jiejun, Losada, Maria C, Brown, Michelle L, Young, Katherine, Butterton, Joan R, Paschke, Amanda, Chen, Luke F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777782/
http://dx.doi.org/10.1093/ofid/ofaa439.1754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777782/
http://dx.doi.org/10.1093/ofid/ofaa439.1754

Ejemplares similares